阴道残端近距离放疗后剂量密集化疗治疗早期高危中危子宫内膜癌的II期试验
这项II期试验纳入32例可评估的早期子宫内膜癌术后患者,先接受阴道残端近距离放疗(2100 cGy),再接受3周期卡铂(AUC 6)联合剂量密集紫杉醇(80 mg/m2)周疗。主要终点为完成两种治疗的比例,结果为84.4%(27/32);方案耐受性良好,但无复发生存和总生存数据尚未成熟。
要点
- 84.4%(27/32)患者按方案完成阴道残端近距离放疗联合3周期剂量密集化疗。
- 阴道残端近距离放疗急性毒性以1–2级胃肠道、泌尿生殖系统症状和乏力为主。
- 剂量密集化疗相关急性毒性包括输注反应和中性粒细胞减少,远期毒性多为1–2级并可缓解。
核心结论
- 阴道残端近距离放疗后予3周期剂量密集紫杉醇联合卡铂在富集的高危中危早期子宫内膜癌患者中耐受性良好,具有应用前景。
- 无复发生存和总生存结局尚未成熟。
研究设计与样本
- II期试验,纳入32例可评估的早期子宫内膜癌术后患者,中位年龄64.5岁。
- 干预为阴道残端近距离放疗(2100 cGy)后3周期卡铂(AUC 6)联合剂量密集紫杉醇(80 mg/m2)周疗,需在术后12周内开始。
- 主要终点为完成阴道残端近距离放疗和剂量密集化疗的患者比例。
主要发现
- 27/32(84.4%)患者按方案完成治疗;未完成原因包括肾功能不全、紫杉醇反应和治疗拒绝。
- 组织学以子宫内膜样癌为主(18/32,56.3%),全面分期21/32(65.6%),Ib期18/32(56.3%)。
- 阴道残端近距离放疗完成中位时间为11天,全部患者完成3次治疗。
- 阴道残端近距离放疗急性毒性包括1级和2级胃肠道、泌尿生殖系统症状及乏力;剂量密集化疗急性毒性包括输注反应和中性粒细胞减少。
- 多数远期毒性为1级或2级,随时间缓解。
关键数值与推荐
- 阴道残端近距离放疗剂量为2100 cGy。
- 卡铂剂量为AUC 6,紫杉醇为80 mg/m2周疗,共3周期。
- 治疗需在术后12周内开始。
临床怎么用
- 对于富集高危中危因素的早期子宫内膜癌术后患者,可考虑阴道残端近距离放疗后序贯3周期剂量密集紫杉醇联合卡铂方案。
- 治疗期间需关注肾功能、输注反应和中性粒细胞减少,并进行毒性监测。
局限性
- 为单臂II期试验,样本量有限(32例可评估)。
- 无复发生存和总生存数据尚未成熟,无法评估长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the feasibility of vaginal cuff brachytherapy (VCB) followed by 3 cycles of dose dense paclitaxel and carboplatin chemotherapy (ddTC) in enriched, high-intermediate risk (H-IR) patients with early stage endometrial cancer following hysterectomy. METHODS: A phase II trial of early stage endometrial cancer patients treated with VCB (2100 cGy) followed by three cycles of carboplatin (AUC 6) and dose dense paclitaxel (80 mg/m2) weekly within 12-weeks of surgery was conducted. The primary endpoint was the proportion of patients completing both VCB and ddTC. Secondary outcomes include short and long-term toxicities, recurrence rate and sites, and progression free survival. Toxicity assessments were patient reported as well as those resulting in delays or dose modifications. RESULTS: A total of 32 evaluable patients with median age of 64.5 years were included. Most patients were endometrioid histology (18/32, 56.3%) and fully staged (21/32, 65.6%) to stage Ib (18/32, 56.3%). In total, 27/32 (84.4%) patients completed treatment per protocol. Protocol non-completion included renal insufficiency, paclitaxel reaction, and treatment refusal. Median time to VCB completion was 11 days with all patients completing three fractions of VCB. Acute toxicities with VCB included grade 1 and 2 gastrointestinal, genitourinary and fatigue symptoms. Acute toxicities associated with ddTC included infusion reaction and neutropenia. Most reported long-term toxicities were grade 1 or 2 and resolved with time. CONCLUSIONS: Treatment with VCB followed by three cycles of ddTC is well-tolerated with promising utility for treatment in enriched high-intermediate risk endometrial cancer patients. Recurrence-free and overall survival outcomes are not yet mature.
引用
- Castellano T, John Maxwell IV, Adam Walter J, et al. Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence. Gynecol Oncol. 2020. PMID: 33358492. doi:10.1016/j.ygyno.2020.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。